Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 4, 2006, Pages 871-876

  Matsushita, Kunihiro ^a   Yatsuya, Hiroshi ^a   Tamakoshi, Koji ^a   Wada, Keiko ^a   Otsuka, Rei ^a   Takefuji, Seiko ^a   Sugiura, Kaichiro ^a   Kondo, Takahisa ^a   Murohara, Toyoaki ^a   Toyoshima, Hideaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiovascular disease prevention; Inflammation; Metabolic syndrome; Risk factors

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CELL MARKER; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER; CARDIOVASCULAR DISEASE; CELL TRANSFORMATION; DETERIORATION; DISEASE ASSOCIATION; EDUCATION PROGRAM; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; STATISTICAL SIGNIFICANCE;

ADIPONECTIN; AGE FACTORS; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; MALE; METABOLIC SYNDROME X; MIDDLE AGED; REGRESSION ANALYSIS; SMOKING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646688394     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000208363.85388.8f     Document Type: Article

References (42)

1. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation. 2002;106:3143-3421.
2. Garg R, Tripathy D, Dandona P. Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic interventions. Curr Drug Targets. 2003;4:487-492.
3. Reilly MP, Rader DJ. The metabolic syndrome. More than the sum of its parts? Circulation. 2003;108:1546-1551.
4. Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, Zhang H, Murata C, Otsuka R, Zhu S, Toyoshima H. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord. 2003;27:443-449.
5. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14719 initially healthy Am women. Circulation. 2003;107:391-397.
6. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Satter N; West of Scotland Coronary Prevention Study Group. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51:1596-1600.
7. Ridker PM, Wilson PWF, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004;109:2818-2825.
8. Xydakis AM, Case CC, Jones PH, Hoogeveen RC, Liu M, O'Brian SE, Nelson KW, Ballantyne CM. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab. 2004;89:2697-2703.
9. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circulating IL-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol. 2002;22:1668-1673.
10. Cesari M, Penninx BWJH, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M. Inflammatory markers and onset of cardiovascular events. Results from the Health ABC Study. Circulation. 2003;108:2317-2322.
11. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunward E; Cholesterol And Recurrent Events (CARE) Investigators. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149-2153.
12. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:29-33.
13. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T. Adiponectin as a biomarker of the metabolic syndrome. Circ J. 2004;68:975-981.
14. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288-1295.
15. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Novel modulator for endothelial adhesion molecules. Adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473-2476.
16. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NFκB signaling through a cAMP-dependent pathway. Circulation. 2000;102:1296-1301.
17. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 2000;96:1723-1732.
18. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103:1057-1063.
19. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004;109:1955-1959.
20. The Examination Committee of Criteria for 'Obesity Disease' in Japan, Japan Society for the Study of Obesity. New criteria for 'Obesity Disease' in Japan. Circ J. 2002;66:987-992.
21. Alberti KG, Zimmet P, Shaw J. for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366:1059-1062.
22. The Committee for the Diagnostic Criteria of Metabolic Syndrome (translated by the authors). The definition and diagnostic criteria of metabolic syndrome (In Japanese). J Jpn Soc Int Med. 2005;94:794-809.
23. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003;278:45021-45026.
24. Torres JL, Ridker PM. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curr Opin Cardiol. 2003;18:471-478.
25. Salmenniemi U, Ruotsalainen E, Pihlajamäki J, Vauhkonen I, Kainulainen S, Punnonen K, Vanninen E, Laakso M. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation. 2004;110:3842-3848.
26. Choi KM, Lee J, Lee KW, Seo JA, Oh JH, Kim SG, Kim NH, Choi DS, Baik SH. Comparison of serum concentrations of C-reactive protein, TNF-alpha, and IL 6 between elderly Korean women with normal and impaired glucose tolerance. Diabetes Res Clin Pract. 2004;64:99-106.
27. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and IL-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280:E745-E751.
28. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is IL-6 the link? Atherosclerosis. 2000;148:209-214.
29. Febbraio MA, Pedersen BK. Muscle-derived IL-6: mechanisms for activation and possible biological roles. FASEB J. 2002;16:1335-1347.
30. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO. IL-6-deficient mice develop mature-onset obesity. Nat Med. 2002;8:75-79.
31. DiCosmo BF, Picarella D, Flavell RA. Local production of human IL-6 promotes insulitis but retards the onset of insulin-dependent diabetes mellitus in non-obese diabetic mice. Int Immunol. 1994;6:1829-1837.
32. Powers AC. Diabetes mellitus. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Principles of Internal Medicine. 16th ed. New York, NY: McGraw-Hill; 2005:2152-2180.
33. Festa A, Hanley AJ, Tracy RP, D'Agostino R Jr, Haffner SM. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation. 2003;108:1822-1830.
34. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
35. Pischon T, Girman CJ, Hotamisligil GS, RIfai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. J Am Med Assoc. 2004;291:1730-1737.
36. Nakamura T, Tsubono Y, Kameda-Takemura K, Funahashi T, Yamashita S, Hisamichi S, Kita T, Yamamura T, Matsuzawa Y. Magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees. Jpn Circ J. 2001;65:11-17.
37. McNeely MJ, Boyko EJ, Shofer JB, Newell-Morris L, Leonetti DL, Fujimoto WY. Standard definitions of overweight and central adiposity for determining diabetes risk in Japanese Americans. Am J Clin Nutr. 2001;74:101-107.
38. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-419.
39. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245-1250.
40. Jialal I, Stein D, Balls D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103:1933-1935.
41. Takeda T, Hoshida S, Nishino M, Tanouchi J, Otsu K, Hori M. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis. 2003;169:155-158.
42. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094-2099.